Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IOVA | US
0.70
7.17%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.46
9.87
10.47
9.87
Iovance Biotherapeutics Inc. a clinical-stage biotechnology company focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies Inc. and changed its name to Iovance Biotherapeutics Inc. in June 2017. Iovance Biotherapeutics Inc. was incorporated in 2007 and is headquartered in San Carlos California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
60.5%1 month
67.2%3 months
84.7%6 months
74.0%-
-
3.80
0.11
0.08
-8.68
78.91
-
-439.25M
3.17B
3.17B
-
-327.64
-
12.97K
-65.36
9.56
21.97
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.53
Range1M
2.13
Range3M
5.39
Rel. volume
0.77
Price X volume
43.09M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Apellis Pharmaceuticals Inc | APLS | Biotechnology | 27.51 | 3.35B | -3.41% | n/a | 179.52% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Amicus Therapeutics Inc | FOLD | Biotechnology | 10.6 | 3.14B | 0.09% | n/a | 335.08% |
Xenon Pharmaceuticals Inc | XENE | Biotechnology | 40.73 | 3.09B | -0.27% | n/a | 1.19% |
Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 49.63 | 3.03B | -2.71% | n/a | 642.15% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -8.68 | 0.76 | Cheaper |
Ent. to Revenue | 78.91 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.80 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 84.69 | 74.67 | Par |
Debt to Equity | 0.11 | -1.82 | Expensive |
Debt to Assets | 0.08 | 0.26 | Cheaper |
Market Cap | 3.17B | 3.73B | Par |